AptarGroup sees Q2 EPS $1.56-$1.64, consensus $1.41

Regarding Aptar’s outlook, Tanda stated, “We expect to build on our solid start to the year as we head into the second quarter, with positive contributions from all three segments. As a leader in dosing, dispensing and protection technologies, we are well positioned across a number of resilient end markets, including medications for chronic diseases and consumer staples that are relied upon by millions of people every day, even in uncertain economic conditions. In addition, our robust, long-standing, in-region for-region supply chain structure allows us to be agile and flexible in a dynamic marketplace.”